Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology

MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the treatment of atopic dermatitis and Phase 2 trial with SB206 gel for the treatment of molluscum contagiosum will be presented at the 77th Annual Meeting of the Annual Meeting of the Society for Investigative Dermatology. The meeting will be held May 8-11, 2019 in Chicago, Illinois.